tiprankstipranks
Titan Pharmaceuticals (TTNP)
NASDAQ:TTNP
US Market

Titan Pharmaceuticals (TTNP) AI Stock Analysis

Compare
791 Followers

Top Page

TT

Titan Pharmaceuticals

(NASDAQ:TTNP)

41Neutral
Titan Pharmaceuticals has a challenging financial outlook with declining revenues and persistent losses, which heavily impact its stock score. While technical indicators suggest some short-term stability, the long-term prospects remain uncertain. The negative P/E ratio and absence of dividends further weigh on its valuation, resulting in a low overall score.

Titan Pharmaceuticals (TTNP) vs. S&P 500 (SPY)

Titan Pharmaceuticals Business Overview & Revenue Model

Company DescriptionTitan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program (TP-2021) for use in combination with ProNeura technology for the treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.
How the Company Makes MoneyTitan Pharmaceuticals generates revenue primarily through the commercialization of its flagship product, Probuphine. The company earns income from product sales, licensing agreements, and royalties. Probuphine, as a treatment for opioid dependence, is sold to healthcare providers and distributed through specialty pharmaceutical distribution channels. Additionally, Titan engages in strategic partnerships and collaborations with other pharmaceutical companies, which can result in upfront payments, milestone payments, and ongoing royalty streams based on product sales.

Titan Pharmaceuticals Financial Statement Overview

Summary
Titan Pharmaceuticals faces substantial financial challenges marked by declining revenues and persistent losses. Despite having no debt, the company's operational inefficiencies and diminishing asset value pose significant risks. Negative cash flows and reliance on external financing add to the financial instability.
Income Statement
20
Very Negative
Titan Pharmaceuticals demonstrates a consistent decline in revenue over recent years, with the latest year showing no revenue generation. Gross profit margins have deteriorated, and the company continues to report substantial net losses, indicating ongoing challenges in achieving profitability. The negative EBIT and EBITDA margins reflect operational inefficiencies and high expenses relative to revenue.
Balance Sheet
35
Negative
The balance sheet shows a strong equity position with no current debt, resulting in a zero debt-to-equity ratio. However, the significant decline in total assets and stockholders' equity over time raises concerns about long-term financial health. The equity ratio remains relatively high, but the shrinking asset base could pose risks if the trend continues.
Cash Flow
25
Negative
Cash flow analysis indicates negative operating cash flow and free cash flow in recent years, reflecting difficulties in generating cash from operations. Although there has been a slight improvement in free cash flow year-over-year, the company is still heavily reliant on financing activities to cover its cash requirements.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
0.00184.00K60.00K1.53M4.84M
Gross Profit
0.0072.00K-136.00K1.33M4.37M
EBIT
-4.56M-7.28M-10.23M-9.35M-7.35M
EBITDA
-4.56M-7.17M-10.04M-9.13M-7.06M
Net Income Common Stockholders
-4.71M-5.57M-10.18M-8.11M-20.73M
Balance SheetCash, Cash Equivalents and Short-Term Investments
2.83M6.76M2.94M6.04M5.41M
Total Assets
2.92M8.09M4.06M7.99M8.09M
Total Debt
0.00565.00K187.00K299.00K809.00K
Net Debt
-2.83M-6.20M-2.75M-5.74M-4.60M
Total Liabilities
483.00K1.44M2.69M2.86M4.55M
Stockholders Equity
2.44M6.64M1.36M5.14M3.53M
Cash FlowFree Cash Flow
-3.88M-7.09M-8.18M-7.92M-17.74M
Operating Cash Flow
-3.88M-7.09M-8.18M-7.90M-17.20M
Investing Cash Flow
0.00732.00K0.00-23.00K-540.00K
Financing Cash Flow
-62.00K10.00M4.98M8.84M17.93M

Titan Pharmaceuticals Technical Analysis

Technical Analysis Sentiment
Positive
Last Price4.00
Price Trends
50DMA
3.68
Positive
100DMA
3.66
Positive
200DMA
4.59
Negative
Market Momentum
MACD
0.03
Positive
RSI
54.21
Neutral
STOCH
29.60
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TTNP, the sentiment is Positive. The current price of 4 is above the 20-day moving average (MA) of 3.69, above the 50-day MA of 3.68, and below the 200-day MA of 4.59, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 54.21 is Neutral, neither overbought nor oversold. The STOCH value of 29.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TTNP.

Titan Pharmaceuticals Risk Analysis

Titan Pharmaceuticals disclosed 29 risk factors in its most recent earnings report. Titan Pharmaceuticals reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Titan Pharmaceuticals Peers Comparison

Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
68
Neutral
$10.67B32.9114.16%24.81%33.67%
66
Neutral
$1.12B86.383.42%14.88%-86.70%
51
Neutral
$5.69B-231.63%42.53%-15.29%
48
Neutral
$6.86B1.11-50.22%2.47%16.71%1.53%
48
Neutral
$483.24M-63.37%-52.30%27.13%
41
Neutral
$3.23M-103.63%-100.00%28.48%
39
Underperform
$2.35B-27.85%-10.19%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TTNP
Titan Pharmaceuticals
4.00
-2.89
-41.94%
NBIX
Neurocrine
108.31
-29.30
-21.29%
INVA
Innoviva
18.07
3.41
23.26%
SAGE
SAGE Therapeutics
7.77
-8.81
-53.14%
XENE
Xenon
31.46
-10.75
-25.47%
AXSM
Axsome Therapeutics
109.75
37.58
52.07%

Titan Pharmaceuticals Corporate Events

Executive/Board ChangesBusiness Operations and Strategy
Titan Pharmaceuticals Appoints Chay Weei Jye as CEO
Positive
Dec 6, 2024

Chay Weei Jye has been appointed as the new CEO, bringing extensive IT leadership experience from roles at Zchwantech, Affin Bank Berhad, and Malaysian Airlines. His strategic expertise in technology solutions and enterprise architecture is expected to drive the company’s growth, making this a significant development for investors watching the company’s trajectory.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.